Teva Pharmaceutical Industries Limited (TEVA)

Market Cap	27.50B
Revenue (ttm)	16.78B
Net Income (ttm)	713.00M
Shares Out	1.15B
EPS (ttm)	0.62
PE Ratio	38.84
Forward PE	9.16
Dividend	n/a
Ex-Dividend Date	n/a

Volume	13,092,659
Open	24.38
Previous Close	24.46
Day's Range	23.61 - 24.42
52-Week Range	12.47 - 25.00
Beta	0.70
Analysts	Strong Buy
Price Target	25.86 (+7.89%)
Earnings Date	Nov 5, 2025

About TEVA

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The com...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1901
• Employees: 36,830
• Stock Exchange: NYSE
• Ticker Symbol: TEVA
• Website: https://www.tevapharm.com

Financial Performance

In 2024, Teva Pharmaceutical's revenue was $16.54 billion, an increase of 4.40% compared to the previous year's $15.85 billion. Losses were -$1.64 billion, 193.2% more than in 2023.

Analyst Summary

According to 7 analysts, the average rating for TEVA stock is "Strong Buy." The 12-month stock price target is $25.86, which is an increase of 7.89% from the latest price.

Price Target

$25.86

(7.89% upside)

Analyst Consensus: Strong Buy